癌症患者MyoD1甲基化状态和表达水平与DNMT1表达水平的相关性。

Sahar Khojastehpour, Farshad Foroughi, Nematollah Gheibi, Zahra Mohammadi, Mohammad Hossein Ahmadi, Neda Nasirian, Amirhosein Maali, Mehdi Azad
{"title":"癌症患者MyoD1甲基化状态和表达水平与DNMT1表达水平的相关性。","authors":"Sahar Khojastehpour,&nbsp;Farshad Foroughi,&nbsp;Nematollah Gheibi,&nbsp;Zahra Mohammadi,&nbsp;Mohammad Hossein Ahmadi,&nbsp;Neda Nasirian,&nbsp;Amirhosein Maali,&nbsp;Mehdi Azad","doi":"10.18502/ijhoscr.v17i3.13303","DOIUrl":null,"url":null,"abstract":"<p><p><b>Background:</b> Breast cancer (BC) is the most common malignancy in women worldwide. The methylation status of <i>MyoD1</i>, a tumor suppressor gene, is enrolled in various cancers, i.e., BC. Various studies showed the impact of <i>MyoD1</i> epigenetic dysregulation in BC. This study aimed to investigate the methylation status and expression level of <i>MyoD1</i> in BC patients and its association with the expression of <i>DNMT1</i>. <b>Materials and Methods:</b> This case-control study was conducted on 30 cases (pathology-confirmed ductal carcinoma) and 18 controls (fibroadenoma and fibrocystic masses), referred to Velayat Hospital, Qazvin, Iran. The expression of the <i>MyoD1</i> and <i>DNMT1</i> and the promoter methylation of the <i>MyoD1</i> were evaluated in tissue blocks of BC patient masses using qRT-PCR and MS-PCR assays, respectively. SPSS 24.0 was used to analyze the data. <b>Results:</b> The <i>MyoD1</i> promoter is hypermethylated in BC patients compared to controls (p =0.001). The expression level of <i>MyoD1</i> in BC patients was significantly reduced compared to controls (fold change =0.13, p =0.042). In addition, in BC patients, the reduced expression level of <i>MyoD1</i> was significantly associated with methylation of the <i>MyoD1</i> promoter (p =0.001). There is no significant difference between the expression level of <i>DNMT1</i> in BC patients and controls (p =0.197). A significant association is found between the expression of <i>DNMT1</i> and the methylation status of the <i>MyoD1</i> promoter (p =0.038). <b>Discussion:</b> The expression level of <i>MyoD1</i> is affected by the methylation status of the promoter of this gene. Moreover, the expression level and methylation status of <i>MyoD1</i> are correlated with clinical parameters.</p>","PeriodicalId":94048,"journal":{"name":"International journal of hematology-oncology and stem cell research","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2023-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/7c/cd/IJHOSCR-17-133.PMC10560649.pdf","citationCount":"0","resultStr":"{\"title\":\"The Association of Methylation Status and Expression Level of <i>MyoD1</i> with <i>DNMT1</i> Expression Level in Breast Cancer Patients.\",\"authors\":\"Sahar Khojastehpour,&nbsp;Farshad Foroughi,&nbsp;Nematollah Gheibi,&nbsp;Zahra Mohammadi,&nbsp;Mohammad Hossein Ahmadi,&nbsp;Neda Nasirian,&nbsp;Amirhosein Maali,&nbsp;Mehdi Azad\",\"doi\":\"10.18502/ijhoscr.v17i3.13303\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p><b>Background:</b> Breast cancer (BC) is the most common malignancy in women worldwide. The methylation status of <i>MyoD1</i>, a tumor suppressor gene, is enrolled in various cancers, i.e., BC. Various studies showed the impact of <i>MyoD1</i> epigenetic dysregulation in BC. This study aimed to investigate the methylation status and expression level of <i>MyoD1</i> in BC patients and its association with the expression of <i>DNMT1</i>. <b>Materials and Methods:</b> This case-control study was conducted on 30 cases (pathology-confirmed ductal carcinoma) and 18 controls (fibroadenoma and fibrocystic masses), referred to Velayat Hospital, Qazvin, Iran. The expression of the <i>MyoD1</i> and <i>DNMT1</i> and the promoter methylation of the <i>MyoD1</i> were evaluated in tissue blocks of BC patient masses using qRT-PCR and MS-PCR assays, respectively. SPSS 24.0 was used to analyze the data. <b>Results:</b> The <i>MyoD1</i> promoter is hypermethylated in BC patients compared to controls (p =0.001). The expression level of <i>MyoD1</i> in BC patients was significantly reduced compared to controls (fold change =0.13, p =0.042). In addition, in BC patients, the reduced expression level of <i>MyoD1</i> was significantly associated with methylation of the <i>MyoD1</i> promoter (p =0.001). There is no significant difference between the expression level of <i>DNMT1</i> in BC patients and controls (p =0.197). A significant association is found between the expression of <i>DNMT1</i> and the methylation status of the <i>MyoD1</i> promoter (p =0.038). <b>Discussion:</b> The expression level of <i>MyoD1</i> is affected by the methylation status of the promoter of this gene. Moreover, the expression level and methylation status of <i>MyoD1</i> are correlated with clinical parameters.</p>\",\"PeriodicalId\":94048,\"journal\":{\"name\":\"International journal of hematology-oncology and stem cell research\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2023-07-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/7c/cd/IJHOSCR-17-133.PMC10560649.pdf\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"International journal of hematology-oncology and stem cell research\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.18502/ijhoscr.v17i3.13303\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"International journal of hematology-oncology and stem cell research","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.18502/ijhoscr.v17i3.13303","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

摘要

背景:癌症是全球女性最常见的恶性肿瘤。肿瘤抑制基因MyoD1的甲基化状态被纳入各种癌症,即BC。各种研究表明MyoD1表观遗传学失调对BC的影响。本研究旨在探讨BC患者MyoD1的甲基化状态和表达水平及其与DNMT1表达的关系。材料和方法:这项病例对照研究对30例(经病理证实的导管癌)和18例对照(纤维腺瘤和纤维囊性肿块)进行,这些病例被转诊至伊朗Qazvin Velayat医院。分别使用qRT-PCR和MS-PCR测定在BC患者肿块的组织块中评估MyoD1和DNMT1的表达以及MyoD1的启动子甲基化。采用SPSS 24.0软件对数据进行统计分析。结果:与对照组相比,BC患者的MyoD1启动子高度甲基化(p=0.001)。与对照组比较,BC患者MyoD1的表达水平显著降低(倍数变化=0.13,p=0.042)。此外,在BC患者中,MyoD1的表达水平降低与MyoD1启动子的甲基化显著相关(p=0.001)。不列颠哥伦比亚省患者和对照组的DNMT1表达水平没有显著差异(p=0.017)MyoD1受该基因启动子甲基化状态的影响。此外,MyoD1的表达水平和甲基化状态与临床参数相关。
本文章由计算机程序翻译,如有差异,请以英文原文为准。

The Association of Methylation Status and Expression Level of <i>MyoD1</i> with <i>DNMT1</i> Expression Level in Breast Cancer Patients.

The Association of Methylation Status and Expression Level of MyoD1 with DNMT1 Expression Level in Breast Cancer Patients.

Background: Breast cancer (BC) is the most common malignancy in women worldwide. The methylation status of MyoD1, a tumor suppressor gene, is enrolled in various cancers, i.e., BC. Various studies showed the impact of MyoD1 epigenetic dysregulation in BC. This study aimed to investigate the methylation status and expression level of MyoD1 in BC patients and its association with the expression of DNMT1. Materials and Methods: This case-control study was conducted on 30 cases (pathology-confirmed ductal carcinoma) and 18 controls (fibroadenoma and fibrocystic masses), referred to Velayat Hospital, Qazvin, Iran. The expression of the MyoD1 and DNMT1 and the promoter methylation of the MyoD1 were evaluated in tissue blocks of BC patient masses using qRT-PCR and MS-PCR assays, respectively. SPSS 24.0 was used to analyze the data. Results: The MyoD1 promoter is hypermethylated in BC patients compared to controls (p =0.001). The expression level of MyoD1 in BC patients was significantly reduced compared to controls (fold change =0.13, p =0.042). In addition, in BC patients, the reduced expression level of MyoD1 was significantly associated with methylation of the MyoD1 promoter (p =0.001). There is no significant difference between the expression level of DNMT1 in BC patients and controls (p =0.197). A significant association is found between the expression of DNMT1 and the methylation status of the MyoD1 promoter (p =0.038). Discussion: The expression level of MyoD1 is affected by the methylation status of the promoter of this gene. Moreover, the expression level and methylation status of MyoD1 are correlated with clinical parameters.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信